Biogen Inc. $BIIB Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP cut its stake in Biogen Inc. (NASDAQ:BIIB) by 6.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 873,094 shares of the biotechnology company’s stock after selling 55,402 shares during the period. Dimensional Fund Advisors LP owned 0.60% of Biogen worth $122,293,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Israel Discount Bank of New York bought a new position in shares of Biogen during the third quarter worth about $204,000. Cresset Asset Management LLC lifted its position in Biogen by 4.1% in the 3rd quarter. Cresset Asset Management LLC now owns 91,217 shares of the biotechnology company’s stock valued at $12,778,000 after purchasing an additional 3,567 shares during the last quarter. Victory Capital Management Inc. boosted its stake in Biogen by 72.5% during the 3rd quarter. Victory Capital Management Inc. now owns 212,962 shares of the biotechnology company’s stock valued at $29,832,000 after purchasing an additional 89,530 shares during the period. Focus Partners Advisor Solutions LLC boosted its stake in Biogen by 17.0% during the 3rd quarter. Focus Partners Advisor Solutions LLC now owns 7,387 shares of the biotechnology company’s stock valued at $1,134,000 after purchasing an additional 1,076 shares during the period. Finally, Elo Mutual Pension Insurance Co grew its position in Biogen by 20.5% in the 3rd quarter. Elo Mutual Pension Insurance Co now owns 21,602 shares of the biotechnology company’s stock worth $3,026,000 after purchasing an additional 3,668 shares during the last quarter. 87.93% of the stock is currently owned by institutional investors.

Biogen News Roundup

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen presented additional Phase 1b data for salanersen in spinal muscular atrophy (SMA) showing new motor milestones, a supportive safety profile over one year, and the launch of a global Phase 3 program — news that increases the drug’s commercial and clinical probability upside. GlobeNewsWire: Salanersen Phase 1b
• Positive Sentiment: Additional media coverage emphasizes salanersen’s once-yearly dosing potential and the potential to address patients with suboptimal response to prior gene therapy — a clear positive for BIIB’s late-stage pipeline narrative. The Pharma Letter: Salanersen data
• Positive Sentiment: Analyst and market commentary is supportive: a Barchart piece notes BIIB is outperforming the healthcare sector, and Zacks highlights BIIB as a strong value stock — both reinforce investor sentiment and may attract relative-value and sector-rotation flows. Barchart: BIIB outperforming Zacks: Value case
• Positive Sentiment: Macro/market commentary from industry voices (Josh Brown) argues large-cap biotech is “growth without disruption risk,” which can boost investor appetite for established biotech names like BIIB. Josh Brown / 247wallst
• Neutral Sentiment: Biogen’s presentation transcript from the Leerink Global Healthcare Conference is available; such presentations can clarify near-term strategy but typically have incremental impact unless new guidance/data are revealed. Seeking Alpha: Leerink transcript
• Neutral Sentiment: Coverage summarizing Q4 winners/losers versus peers provides context on relative performance but did not report a new catalyst specific to Biogen. Yahoo Finance: Q4 winners & losers
• Neutral Sentiment: Short-interest entries in the feed show contradictory/erroneous values (zeros and NaN); there’s no reliable evidence here of a material increase in short-selling pressure.
• Neutral Sentiment: An article about a biogenic carbon removal project (Svante) appears unrelated to Biogen the biotech and is unlikely to affect BIIB’s stock. Financial Post: Svante CDR project

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. Tudor Pickering set a $201.00 price target on shares of Biogen in a research note on Monday, February 9th. Morgan Stanley set a $190.00 price objective on Biogen in a report on Sunday, February 8th. Weiss Ratings restated a “hold (c-)” rating on shares of Biogen in a research report on Monday, December 29th. Truist Financial lifted their target price on Biogen from $190.00 to $193.00 and gave the company a “hold” rating in a research note on Monday, February 9th. Finally, Mizuho boosted their price target on Biogen from $207.00 to $236.00 and gave the stock an “outperform” rating in a research report on Tuesday, February 10th. Twelve research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat, Biogen has a consensus rating of “Hold” and a consensus price target of $205.04.

Insider Transactions at Biogen

In other news, insider Priya Singhal sold 2,660 shares of Biogen stock in a transaction on Monday, February 9th. The stock was sold at an average price of $199.83, for a total transaction of $531,547.80. Following the transaction, the insider directly owned 8,043 shares in the company, valued at approximately $1,607,232.69. This trade represents a 24.85% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.18% of the company’s stock.

Biogen Trading Up 1.1%

Shares of NASDAQ:BIIB opened at $190.48 on Thursday. The company has a 50 day moving average of $183.84 and a 200-day moving average of $166.32. The company has a current ratio of 2.68, a quick ratio of 2.03 and a debt-to-equity ratio of 0.34. The firm has a market cap of $27.95 billion, a P/E ratio of 21.62, a P/E/G ratio of 1.50 and a beta of 0.15. Biogen Inc. has a twelve month low of $110.04 and a twelve month high of $202.41.

Biogen (NASDAQ:BIIB) last posted its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 EPS for the quarter, beating analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The business had revenue of $2.28 billion for the quarter, compared to analyst estimates of $2.21 billion. During the same quarter last year, the business earned $3.44 earnings per share. The business’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. As a group, analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.